

# A Study of Echo-Cardiographic Findings and Factors Affecting Severity of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients

Sandeep Jain<sup>1</sup>, Adil Aziz<sup>2</sup>, Pradeep Jain<sup>3</sup>

<sup>1</sup>Associate Professor, Department of Medicine, JNUIMSRC, JAIPUR, Rajasthan, India

<sup>2</sup>Associate Professor, Department of Medicine, JNUIMSRC, JAIPUR, Rajasthan, India

<sup>3</sup>Assistant Professor, Department of Medicine, JNUIMSRC, JAIPUR, Rajasthan, India

Received: 15-01-2023 / Revised: 12-02-2023 / Accepted: 13-03-2023

Corresponding author: Dr. Sandeep Jain

Conflict of interest: Nil

## Abstract

**Introduction:** COPD (Chronic Obstructive Pulmonary Disease) is most prevalent respiratory ailment affecting the Indian population and contributes significantly to the mortality and morbidity of the disease. CVE (cardiovascular event) is the most prevalent cause of comorbidities and the second most common cause of mortality, next to respiratory failure. Most common complication of COPD is Pulmonary hypertension (PHTN).

**Objectives:** 1) To find out the prevalence of cardiovascular involvement in COPD patients. 2) To study the relation between severity of PHTN and culprit-factors, if exists.

**Material and Method:** this hospital based cross sectional study was conducted at Department of Medicine, JNUIMSRC, Jaipur, Rajasthan, sample size was 102 randomly selected cases of clinically suspected COPD who attended OPD or got admitted in the Department. Their data were collected and analyzed with help of suitable statistical software.

**Result:** In the present study, among 102 patients, 82 (80.39%) were males and 20 (19.6%) were female. Majority of the patients (90.19%) were smokers. The mean duration of tobacco use was 30.89± 6.80 pack years. Tricuspid regurgitation was measurable in 42(41.17%) patients. Pulmonary hypertension was observed in 38 (37.25 %) and cor-pulmonale in 20 (19.60%) patients. 16 patients (15.68 %) had left ventricular diastolic dysfunction.

Mild PHTN was observed in 13 (34.21%) patients. Moderate PHTN was observed in 15 (39.47 %) patients. Severe PHTN was observed in 10(26.32%) patients. As the severity of COPD increases frequency of PHTN also increases. The patients with PHTN were relatively older ( $p < 0.001$ ). Patients with PHTN experienced significantly more number of exacerbations ( $p < 0.001$ ). Smoking is also a positive factor in development of PHTN ( $p < 0.001$ ).

**Conclusion:** Echo-Cardiography is a helpful tool for timely management of cardiovascular event in these patients.

**Keywords:** COPD, Echo-cardiography, PHTN, Cor-Pulmonale.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

## Introduction

Chronic obstructive pulmonary disease (COPD), represents an important public health challenge that is both preventable and treatable [1]. Globally the COPD

burden is projected to increase in coming decades because of continued exposure to risk factors and aging [2]. Chronic obstructive pulmonary disease is characterized by persistent airflow

limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients [3].

In India the prevalence rate of COPD in males varies from 2.12% to 9.4% & 1.4% to 4.08% and in females varies from 1.33% to 1.49% & 1.2% to 2.55% in studies conducted from North India and South India respectively [4]. COPD also has significant systemic effects that lead to comorbid conditions. COPD has considerable effects on cardiac function including that of right ventricle and left ventricle as well as of the pulmonary blood vessels [5]. Most of the increased mortality associated with COPD is due to cardiac disease [6]. Pulmonary hypertension (PHTN) is the principle cardiovascular complication encountered in COPD. Right ventricular dysfunction (Cor-Pulmonale) is common in COPD patients particularly those with a low oxygen saturation [7]. The early recognition and management of PHTN may lead to prolonged survival and improved quality of life [8]. In US, Cor-Pulmonale averages about 6 to 7% of all types of adult heart disease and COPD is the most common cause. In Delhi, the incidence has been estimated to about 16% [9] among COPD patients.

The diagnosis of cardiac dysfunction in the setting of COPD poses a major challenge to the physicians. The clinical presentation and physical signs may be similar. Clinical examination, chest radiograph and electrocardiography may not yield a confirmatory diagnosis in many cases. Cardiac catheterization remains the "gold standard" for the measurement of pulmonary arterial pressures [7]. However this procedure is not feasible in all patients due to several reasons. Early and appropriate diagnosis of cardiac dysfunction may result in a significant

decline in morbidity and mortality. Echocardiography provides a non-invasive method to evaluate cardiac status like - right ventricular (RV) function, RV filling pressure, tricuspid regurgitation and left ventricular function [10]. Many studies have confirmed that echocardiographically derived estimates of pulmonary artery pressure (PAP) correlate closely with those derived by cardiac catheterization [11,12] Echocardiography has the advantage of repeatability and has no contraindications. It can also be used in very sick patients at their bed side.

Therefore, this study was planned to find out the utility of echocardiography in the assessment of cardiac dysfunction in COPD patients.

### Material and Methods

Present study was carried out among 102 randomly selected cases of clinically suspected COPD who attended OPD or got admitted in the Department of Medicine, JNUIMSRC, Jaipur, Rajasthan. Informed consent was taken from all of them for participation in the study. This study was conducted after approval by Institutional Ethical Committee. This was an observational, cross sectional study. The 102 patients selected underwent spirometry and were classified into mild, moderate, severe and very severe COPD as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015 guidelines. Every patient with detailed clinical history (including grade of dyspnea, smoking status and frequency of exacerbation) or physical finding suggestive of COPD had undergone a routine investigation such as CBC, ESR, chest x-ray, spirometry, sputum for AFB by ziehl-nelson method., blood sugar, liver function tests, renal function tests, ECG, and Echo-cardiography.

The chi-square test and Fisher's exact test were used for the analysis of qualitative data. Student's 't' test was used for comparison of data summarized as mean and standard deviation. Results were


expressed as means ± standard deviation (SD) and as relative frequencies. Statistical significance was set at  $p < 0.05$ .

**Results:**

In the present study, among 102 patients, 82 (80.39%) were males and 20 (19.6%) were female, majority (52.94%) of the patients were in the age group of 50 to 59 years. The mean duration of illness was  $7.30 \pm 1.80$  years. Maximum number of patients (78.43%) had symptoms for less than 10 years and (21.56 %) of patients had symptoms for  $\geq 10$  years. Nearly 2/3<sup>rd</sup> of the patients had severe and very severe disease according to the GOLD classification. (Table 1) Majority of the patients (90.19%) were smokers. The mean duration of tobacco use was  $30.89 \pm 6.80$  pack years. Tricuspid regurgitation was measurable in 42(41.17%) patients. Pulmonary hypertension was observed in 38 (37.25 %)

and corpulmonale in 20 (19.60%) patients. 16 patients (15.68%) had left ventricular diastolic dysfunction. (Graph 1)

Mild PHTN was observed in 13 (34.21%) patients. Moderate PHTN was observed in 15 (39.47 %) patients. Severe PHTN was observed in 10(26.32%) patients. Majority (32 out of 38 patients) had severe and very severe COPD. As the severity of COPD increases severity of PHTN also increases. (Table 2) The patients with PHTN were relatively older ( $p < 0.001$ ). There was no significant difference in the sex distribution according to the presence of PHTN ( $p = 0.3$ ). The subjects with PHTN had significantly longer duration of the illness ( $p < 0.001$ ). Patients with PHTN experienced significantly more number of exacerbations ( $p < 0.001$ ). Smoking is also a positive factor in development of PHTN ( $p < 0.001$ ). (Table 3)



**Graph 1: Distribution according to 2D Echocardiographic findings:**

**Table 1: Severity of COPD according to GOLD classification:**

GOLD stage	No. Of patients	Percentage
Mild	18	17.64%
Moderate	22	21.56%
Severe	36	35.30%
Very severe	26	25.50%
<b>Total</b>	<b>102</b>	<b>100.00%</b>

**Table 2: Severity of PHTN in relation to Severity of COPD :**

Severity of COPD	Severity of PHTN		
	Mild	Moderate	Severe
Mild (18)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Moderate (22)	5 (83.33%)	1 (16.67%)	0 (0.00%)
Severe (36)	7 (41.18%)	6 (35.29%)	4 (23.53%)
Very severe (26)	1 (6.67%)	8 (53.33%)	6 (40.00%)

**Table 3: A Comparative Study of Factors Affecting Development Of PHTN In COPD Patients**

Variables	PHTN		P value
	Present [n=38]	Absent [n=64]	
1. Age in years	59.30 ± 4.10	51.50 ± 4.80	<0.001
2. Duration of illness in years	9.90 ± 1.50	5.80 ± 2.60	<0.001
3. Pack years	38.00 ± 8.90	26.60 ± 12.90	<0.001
4. No of exacerbations(in previous year)	2.10 ± 0.67	0.67 ± 0.69	<0.001

Mean ±SD

## Discussions

Chronic obstructive pulmonary disease is known to be associated with various cardiac co-morbidities. The pathogenesis of pulmonary vascular disease in COPD is likely multi-factorial. [13] Pulmonary vascular disease associated with COPD increases morbidity and worsens survival. The Lung Health Study [13] showed that a substantial proportion of deaths in patients with mild COPD was the result of cardiovascular complications. Increased cardiovascular mortality has been seen particularly in patients older than 65 years with COPD. Pulmonary Hypertension (PHTN) is the principle cardiovascular complication encountered in COPD patients. Pulmonary Hypertension in the adult is said to be present when the Mean Pulmonary Artery Pressure is 25 mm Hg or more at rest or 30mmhg or more with exercise. The severity of Pulmonary Hypertension tends to correlate with the degree of airflow obstruction and severity of hypoxemia [14,15]. Chronic Cor-Pulmonale is a consequence of the increased work of right ventricle, almost invariably due to Pulmonary Hypertension. Evidence of Cor-Pulmonale was found in 40% of patients with COPD in one autopsy study [16]. Pulmonary hypertension and RV dysfunction are well known to

complicate the course of illness and adversely affect the survival and quality of life. The presence of PHTN leads to progressive worsening of RV function, resulting in right heart failure.

Clinical signs are not always confirmatory in the assessment of cardiovascular co-morbidities in COPD as there is overlap in symptoms and signs. [17] Furthermore the clinical signs occur late, far after the development of pulmonary hypertension.

Although cardiac catheterization is considered to be the gold standard for the estimation of pulmonary artery pressure, it has many limitations to be used routinely. There are significant risks [18] and cost issues associated with the procedure whereas Echocardiography on the other hand is a rapid, non-invasive tool to assess the cardiac status in COPD patients. Numerous studies have evaluated the usefulness of echocardiography in evaluation of pulmonary hypertension and cardiac changes secondary to COPD [19-22]. Therefore this study was undertaken to evaluate the utility of echocardiography in assessing cardiac dysfunction in 102 COPD patients and also assessing the relation of PHTN (detected by echo), with the duration and severity of disease, if exists. All the 102 subjects had dyspnea. Majority of them

36 patients (35.29%) had grade 3 dyspnea according to MMRC scale. 5 patients (4.91%) were dyspneic at rest (grade 4). This is in contrast to lower dyspnea reported by de Torres [23] in western population with COPD. He showed 15% patients had grade 3 dyspnea and 4% patients had grade 4 dyspnea. This might reflect the delay in seeking medical attention in Indian patients. The present study had more patients with severe and very severe disease (nearly 2/3rd). In a study by Dave et al [24], the frequency of mild, moderate, severe and very severe COPD was 12%, 19%, 31% and 38% respectively. In a study by Sachin D et al [25], the frequency of mild, moderate, severe and very severe COPD was 8%, 22%, 44% and 26% respectively. Smoking is the most important risk factor for COPD worldwide. In the present study majority of the patients 90.20% were smokers. Most of them used bidi. Twelve females (60%) were smokers. The mean duration of tobacco use was  $30.89 \pm 6.80$  pack years. In study by Gupta S, Khastgiret et al [26] 87.25% were smoker. Hurst JR et al [27] showed 88.67% patients were smoker in his study. The incidence of non-smoker COPD in the study was 9.80 % (10 patients). This was lower than that reported by Behrendt [28] who stated non-smoker COPD to account for about 23-25% of cases in developed nations. This higher proportion reported by Behrendt could be due to the fact that it included former smokers with < 5 pack years. Pulmonary hypertension was observed in 38 (37.25%) patients. 13 patients (34.21%) had mild PHTN. 15 patients (39.47%) had moderate PHTN. Severe PHTN was observed in 10 (26.32%) subjects. The level of PHTN has a prognostic value in COPD. This has been demonstrated by several studies. In one of the study [29], the 5-year survival rates were 50% in mild PHTN, 30% in those with moderate to severe PHTN, and 8% in very severe PHTN. Thus a high degree of PHTN bears poor prognosis. The incidence of PHTN in moderate, severe and very severe

COPD was 27.27%, 47.22% and 57.69% respectively. Gupta et al [30] showed an overall incidence of PHTN in 42.5% patients and frequencies in mild, moderate, severe and very severe COPD was 11%, 9%, 40% and 33.3% respectively. In the present study none of the patients with mild COPD had PHTN. This supports the notion that the incidence of PHTN increases with advanced COPD [31]. The incidence of cor pulmonale was 19.60% (20 patients) in our study as evidence by RV dilatation (more than 2.6 cm.) Whereas Gupta N K et al [30] reported cor pulmonale in 17.5% of patients. [31]

### Conclusion

The present study has concluded that cardiovascular co-morbidities are common in COPD patients and Echo-Cardiography is useful for accurate assessment of cardiac status in COPD patients.

**Acknowledgements:** We acknowledge the JNUIMSRC, Jaipur, Rajasthan Hospital physicians, counselling nurses and laboratory staff for their kind cooperation during data collection.

**Competing Interests:** The authors declare that they have no competing interests.

### References

1. World Health Report. Geneva: World Health Organization. Available from URL: <http://www.who.int/whr/2000/en/statistics.htm;2000>.
2. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al. Chronic obstructive pulmonary disease: Current burden and future projections. *Eur. Respir. J* 2006; 27: 397-432.
3. Global Initiative for Chronic Obstructive Lung Disease- Global Strategy for The diagnosis, Management and Prevention of Chronic obstructive pulmonary disease. Revised 2011. [Http://www. goldcopd.com](http://www.goldcopd.com).
4. Jindal SK, Aggarwal AN, Gupta D. A review of population studies from India

- to estimate national burden of COPD and its association with smoking. *Indian J Chest Dis Allied Sci.* 2001; 43:139–47.
5. Mcnee W. Pathophysiology of corpulmonale in COPD, part two. *Am J respircrit Care Med.* 1994; 150:1158-1168.
  6. Mannino DM, Buist AS, Petty TL, et al: lung function and mortality in the United States: data from the first national health and nutrition examination survey follow-up study. *Thorax.* 2003; 58: 388-393.
  7. M.A Higam, D. Dawson, J. Joshi, P. Nihoyannopoulos, N W Morell. Utility of echocardiography in the assessment of pulmonary hypertension secondary to COPD. *Eur. Respir. J.* 2011; 17: 350-355.
  8. James R Klinger, Nicholas S Hill. Right Ventricular dysfunction in Chronic obstructive pulmonary disease. *Evaluation and Management. Chest.* 1991; 99: 715-23.
  9. Fishman's pulmonary disease and disorders , 4<sup>th</sup> ed : 1402-1403, 2008.
  10. Daniels LB, Krummen DE, Blanchard DG. Echocardiography in pulmonary vascular disease. *Cardiol. Clin.* 2004; 22: 383-99.
  11. Yock PG, Popp RL et al. Non-invasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. *Circulation.* 1984; 70: 657-62.
  12. Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. *Eur Heart J.* 1991; 12: 103-11.
  13. Jeremy A. Falk, Steven Kadiev, Gerard J. Criner, Steven M. Scharf, Omar A. Minai, and Philip Diaz "Cardiac Disease in Chronic Obstructive Pulmonary Disease", Proceedings of the American Thoracic Society, National Emphysema Treatment Trial. 2008;5: 543-548.
  14. Scharf SM, et al: Haemodynamic characterization of patients with severe emphysema. *Am respircrit Care Med.* 2002; 166: 314-322.
  15. Doi M, et al: Significance of pulmonary artery pressure in emphysema patients with mild to moderate hypoxemia. *Resrir Med.* 2003; 97:915-920.
  16. Health D, Brewer D, Hicker P. Mechanism and pathology. In: Thomas CC, ed. *Corpulmonale in emphysema.* Springfield: Thomas. 1968, 1-37.
  17. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? *Eur J Heart Fail.* 2006; 8: 706–711.
  18. Groves BM, Badesch DB. Cardiac catheterization of patients with pulmonary hypertension. In: Peacock AJ, Editor. *Pulmonary circulation.* London: Chapman & Hall. 1996: 51 – 67.
  19. Skjaerpe T, Hatle L, diagnosis and assessment of tricuspid regurgitation with Doppler ultrasound. In: Rijsterborgh H, Editor. *Echocardiology.* The Hague: martinusnijhoff. 1981:299-304.
  20. MR Fisher et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. *eurrespir J.* 2007; 30: 914-921.
  21. Selim M, et al. Echocardiographic Assessment of Pulmonary Hypertension in patients with Advanced Lung Disease: *American Journal of Respiratory and Critical Care Medicine.* 2003; 167: 735-740.
  22. J Wing, V Mohan, G Avasthi, R Mahajan, A Bery. Echocardiographic evaluation of right heart in chronic obstructive airway disease cases. In *NAPCON.* 2007:45.
  23. J P de Torres, Ciro Casanova, Concepcion Hernandez, Juan Abreu, Angela Montejo de Garcini, Armando Aguirre-Jaime and Bartolome R Celli.

- Gender associated differences in determinants of quality of life in patients with COPD: a case series study. *Health and Quality of Life Outcomes*. 2006; 4: 72.
24. Dave L, Dwivedi P, Srivastava N, Yadav BS, Dohre R. A study of cardiovascular manifestations of COPD. *Int J Res Health Sci*. 2014 Jul 31;2(3):812-7.
25. Sachin D, Santoshkumar P V, Anandan P T, James P T Evaluation of Cardiovascular Abnormalities In Stable Copd Patients By Echopulmo -con 2014. [weebly.com/upload/2/4/6/5/24652399/abstract-sachin.d](http://weebly.com/upload/2/4/6/5/24652399/abstract-sachin.d)
26. Gupta S, Khastgir T, Gupta MP, Sethi KK, Manoharan S. Clinical, haemodynamic and echocardiographic study in chronic corpulmonale. *JAPI*. 1989; 37(6): 373-376.
27. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010; 363: 1128-38.
28. Behrendt CE. Mild and moderate-to-severe COPD in non-smokers. Distinct demographic profiles. *Chest*. 2005; 128: 1239-44.
29. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, et al. Prognostic factors in COPD patients receiving long term oxygen therapy. *Chest*. 1995; 107: 1193-8.
30. N.K. Gupta, R.K. Agarwal, A.B. Srivatsav, M.L. Ved. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its correlation with the severity of disease. *Lung India*. 2011; 28(2): 105-109.
31. Omar A. Minai, MD, FCCP; Ari Chaouat, and Serge Adnot, Pulmonary Hypertension in COPD: Epidemiology, Significance, and Management: Pulmonary Vascular Disease: The Global Perspective. *Chest*. 2010; 137(6) (Suppl): 39S–51S.
32. Syamsuddin, Edsyaamsuddin. maggot development of maggot: The development of *Hermetia Illucens* larvae as a life cycle balance of the Black Soldier Fly. *Current Science*, 2023; 3(2): 294–299.